J
Jiangsu Yingke Biopharmaceutical
Specialized biopharmaceutical manufacturer of injectable generic drugs
About Jiangsu Yingke Biopharmaceutical
Jiangsu Yingke Biopharmaceutical Co., Ltd. is a biopharmaceutical company established on January 25, 2011, that integrates research and development, manufacturing, and sales. The company is located in the Taizhou National Medical Hi-tech Development Zone, also known as China Medical City.
The firm specializes in the R&D of products in fields including parenteral nutrition, anesthesia, and oncology. It focuses on creating fat emulsion series products, such as its Propofol Medium and Long Chain Fat Emulsion Injection, which was the first of its kind to be approved in China and was selected for the national centralized drug procurement program. Its product lineup also includes both launched and pre-launch drugs like Propofol Injectable Emulsion and various anesthetic creams. The company's business model combines in-house R&D with manufacturing and sales, aiming to become a key player in the fat emulsion segmentation market. Many of its products are listed in the National Essential Drug Catalog.
Jiangsu Yingke Biopharmaceutical operates multiple workshops compliant with new Good Manufacturing Practice (GMP) standards, including facilities for bulk drugs, freeze-dried powder injections, and both small and large-volume injections. Since its inception, the company has achieved significant milestones, passing its first GMP certification in 2013 and being recognized as a "National high-tech Enterprise" in 2015. In June 2023, the company secured $42.2 million in a Series B funding round.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2023 | $41M | $165M | Sherpa Venture Partners · China Life Private Equity Investment · Xinshang Capital · North Venture Capital | ↗ |
Growth signals
Latest recorded traffic for Jiangsu Yingke Biopharmaceutical is 1.3K monthly website visits, up 6400% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Jiangsu Yingke Biopharmaceutical in its local ecosystem
The Jiangsu Yingke Biopharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Sherpa Venture Partners- CIChina Life Private Equity Investment
Xinshang Capital- NCNorth Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Jiangsu Yingke Biopharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jiangsu Yingke Biopharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






